Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 1st GBHI-Conference – Conference Report now available 3rd GBHI conference – program is online Who is a healthy subject? German Pharm-Tox Summit 2017 in Heidelberg 2nd part of Introductory Course in Exploratory Medicines Development scheduled for February 2017 Introductory Course in Exploratory Medicines Development – taking place in our offices in Oberursel! Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Bioequivalence Project Management Hypothalamic Dose linearity SocraTec C&S EMA Charcoal ICF Consultancy Phase I Biopharmaceutical Clinical Monitoring MCID CRA DUS Allergy Dermal irritation Pragmatism GLP Auditing Biopharmaceutics Scientific advice Quality Legal Information Paediatricians Phase IV Pharmacokinetics Pharmacokintetics Macular Patients ADAM Metered dose inhaler Ovulation inhibition Slit lamp microscopy Bioavailability Biometrics WinNonlin Scientific expertise Sample size estimation Anaesthesiologist Database Standard operating procedure Contraception Standardisation Asthma Oncology Local tolerability FIM Statistical programming Absorption windows Phase IIb trials Immunogenicity Clinical pharmacology unit Investigators brochure FDA Phase I Unit Patch IB Legal representative Audit Sore throat DFI Statistical Analysis Plan Clinical development program Authorities Healthy subjects Data Validation Plan Ocular tolerability First in human PAES Phase III Expert Efficacy Quality Assurance Quality Management System Cardiovascular surveillance Dry powder inhaler TTS Data management Dry eye SAS Inspection Life cycle management ANVISA Spacious archive Patch adhesion Sequential designs Intensive assessment station Referral system Ophthalmologist Subcontractor qualification Common cold Elpro Axis Female adolescents Children SOP based Absorption Sensitisation trials Eye disease HRT Glaucoma Experience Edema HTA Patient recruitment Source Data Verification Adrenocortical DPI Centralised procedure IEC Creativity Recruitment rates Early phase Informed Consent Procedure Degeneration Hormone replacement therapy Monitoring Phase IIa trials Pulse oximetry plethysmography Highly variable drugs Protocol development GCP training DDI CDM Inhalatives Safety Competence CDASH Phase II Pilot study Clinical trials PASS CRO OTC Statistical services Non interventional Endpoint Clinical study Biosimilars AGAH Cough Transdermal therapeutic system Network Ophthalmology Pharmacodynamic studies CDSIC Drug Drug Interaction Thuringia US CFR 21 Part 11 MMM Uveitis CDISC Pharmacology Lung Pituitary IMPD Post authorisation COPD Protocol Xerostomia Oncologic network Drug Food Interaction Central surveillance system HPA axis Feasibility In vitro in vivo correlation Oncological patients GCP SDV IVIVC Data Management Plan Good Clinical Practice Training MDI Gynaecological trials US FDA Copyright Ophthalmological trials Steady state Product development Rhine Main area NIS CRF Design development Postmenopausal women  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page